Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/ofid/ofaa232 http://scihub22266oqcxt.onion/10.1093/ofid/ofaa232 C7313828!7313828!32661497     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Open+Forum+Infect+Dis 2020 ; 7 (7): ä Nephropedia Template TP {{tp|p=32661497|t=2020. An Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome Coronavirus 2 |pdf=|usr=}}{{32661497}} gab.com Text An Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome Coronavirus 2 JO: Open Forum Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32661497 #FOAvip As coronavirus disease 2019 cases and deaths continue to expand globally, there is an urgent need to develop, test, and approve effective antiviral therapies. Currently, a majority of clinical trials are evaluating therapies in patients who are already hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) infection. Given that the median time between development of symptoms and need for hospitalization is 1 week, a golden opportunity to intervene early is being missed. Indeed, for many other viral infections, early treatment soon after development of symptoms is associated with decreased mortality, lower hospitalization rates, and lower likelihood of transmission to others. In this study, we advocate for randomized, double-blind, placebo controlled, clinical trials to evaluate promising agents early during SARS CoV-2 infection. Twit Text FOAVip An Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome Coronavirus 2 ????Open Forum Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32661497 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32661497 #FOAvip English Wikipedia <ref>{{Cite pmid|32661497}}</ref> An Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome Coronavirus 2 #MMPMID32661497 Schiffer JT; Johnston C; Wald A; Corey L Open Forum Infect Dis 2020[Jul]; 7 (7): ä PMID32661497show ga As coronavirus disease 2019 cases and deaths continue to expand globally, there is an urgent need to develop, test, and approve effective antiviral therapies. Currently, a majority of clinical trials are evaluating therapies in patients who are already hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) infection. Given that the median time between development of symptoms and need for hospitalization is 1 week, a golden opportunity to intervene early is being missed. Indeed, for many other viral infections, early treatment soon after development of symptoms is associated with decreased mortality, lower hospitalization rates, and lower likelihood of transmission to others. In this study, we advocate for randomized, double-blind, placebo controlled, clinical trials to evaluate promising agents early during SARS CoV-2 infection. äAn Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome(epmc).pdf DeepDyve Pubget Overpricing